Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer†

被引:26
作者
Lococo, Filippo [1 ]
Cesario, Alfredo [1 ,2 ]
Margaritora, Stefano [1 ,3 ]
Dall'Armi, Valentina [4 ]
Mattei, Francesca [4 ]
Romano, Rosalia [1 ]
Porziella, Venanzio [1 ]
Granone, Pierluigi [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Gen Thorac Surg, I-00168 Rome, Italy
[2] IRCCS San Raffaele Pisana, Sci Direct, Rome, Italy
[3] Ctr Oncol Fiorentico CFO, Florence, Italy
[4] IRCCS San Raffaele Pisana, Unit Clin & Mol Epidemiol, Rome, Italy
关键词
Non-small-cell lung cancer; Induction therapy; Radiotherapy; Surgery; CLINICAL-PRACTICE GUIDELINES; STAGE IIIA; CANCER; THERAPY; CHEMOTHERAPY; CHEMORADIATION; RESECTION; N2; RADIOTHERAPY; DIAGNOSIS;
D O I
10.1093/ejcts/ezs622
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The outcome of locally advanced non-small-cell lung cancer (NSCLC) patients with pathological complete response (pCR)-pT0N0 -after induction chemoradiotherapy (IT) followed by surgery has, to date, only rarely been investigated. The long-term results in this highly selected subset of patients were evaluated and reported here to identify any predictive factors associated with prognosis. From January 1992 to December 2009, 195 consecutive locally advanced (T1-T4/N0-2/M0) NSCLC patients underwent IT, and after clinical restaging, 137 were operated upon with radical intent. Among these, 37 (19% of the overall and 27% of the surgical cohort) showed a pCR status and were included in this retrospective analysis. Survival rates and prognostic factors were analysed by the Kaplan-Meier, the log-rank and Cox regression analyses. The mean age and male/female ratio were 61.9 +/- 9.8 years and 33/4, respectively. Before starting IT, the clinical staging was IIb in 2 (5%) patients, IIIa in 20 (54%) and IIIb in 15 (41%). Morbidity and 30-day mortality rates were 27 and 3%, respectively. The overall 3- and 5-year long-term survivals (LTSs) and disease-free survival (DFS) were 67 and 64% and 68 and 71%, respectively. Overall, 17 patients (46%) experienced a recurrence, occurring more frequently in a distant site (32%) than locally (19%). The analysis of the 5-year LTS suggests that (i) the initial single N2 station involvement (P = 0.010); (ii) the resection to a lesser extent than pneumonectomy (P = 0.005) and (iii) the adjuvant therapy (P = 0.005) are all positive prognostic factors. In particular, a 5-year hazard ratio of 8.21 (95% confidence interval 2.16-31.16, P = 0.002) was estimated by Cox regression analysis for subjects who did not undergo adjuvant therapy vs those who did. After induction radiochemotherapy followed by surgery in locally advanced NSCLC, a pCR is achieved in a remarkable proportion of cases (27% in our experience). In such patients, a rewarding LTS (64% at 5 years) could be expected, especially when a single N2 station is involved at diagnosis or when an adjuvant treatment is administered. Nevertheless, recurrences after surgery are quite common (46%) and this evidence deserves further investigations and deeper analysis.
引用
收藏
页码:E71 / E81
页数:11
相关论文
共 26 条
  • [1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805
    ALBAIN, KS
    RUSCH, VW
    CROWLEY, JJ
    RICE, TW
    TURRISI, AT
    WEICK, JK
    LONCHYNA, VA
    PRESANT, CA
    MCKENNA, RJ
    GANDARA, DR
    FOSMIRE, H
    TAYLOR, SA
    STELZER, KJ
    BEASLEY, KR
    LIVINGSTON, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1880 - 1892
  • [2] Diagnosis and management of lung cancer executive summary - ACCP evidence-based clinical practice guidelines (2nd edition)
    Alberts, W. Michael
    [J]. CHEST, 2007, 132 (03) : 1S - 19S
  • [3] The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: Who returns to the surgical arena and who survives
    Cerfolio, Robert J.
    Maniscalco, Lee
    Bryant, Ayesha S.
    [J]. ANNALS OF THORACIC SURGERY, 2008, 86 (03) : 912 - 920
  • [4] Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival
    Cerfolio, Robert James
    Bryant, Ayesha S.
    Jones, Virginia L.
    Cerfolio, Robert Michael
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (04) : 718 - 723
  • [5] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Crino, L.
    Weder, W.
    van Meerbeeck, J.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v103 - v115
  • [6] Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival
    Decaluwe, Herbert
    De Leyn, Paul
    Vansteenkiste, Johan
    Dooms, Christophe
    Van Raemdonck, Dirk
    Nafteux, Philippe
    Coosemans, Willy
    Lerut, Toni
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (03) : 433 - 439
  • [7] Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer
    DeCamp, MM
    Rice, TW
    Adelstein, DJ
    Chidel, MA
    Rybicki, LA
    Murthy, SC
    Blackstone, EH
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (01) : 17 - 27
  • [8] Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:: Mature results of a phase II trial
    Eberhardt, W
    Wilke, H
    Stamatis, G
    Stuschke, M
    Harstrick, A
    Menker, H
    Krause, B
    Müeller, MR
    Stahl, M
    Flasshove, M
    Budach, V
    Greschuchna, D
    Konietzko, N
    Sack, H
    Seeber, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 622 - 634
  • [9] Induction treatment before surgery for non-small cell lung cancer
    Eberhardt, WE
    Albain, KS
    Pass, H
    Putnam, JB
    Gregor, A
    Assamura, H
    Mornex, F
    Senan, S
    Belderbos, J
    Westeel, V
    Thomas, M
    Van Schil, P
    Vansteenkiste, J
    Manegold, C
    Mirimanoff, RO
    Stuschke, M
    Pignon, J
    Rocmans, P
    Shepherds, FA
    [J]. LUNG CANCER, 2003, 42 : S9 - S14
  • [10] Phase II Trial of a Trimodality Regimen for Stage III Non-Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study
    Friedel, Godehard
    Budach, Wilfried
    Dippon, Juergen
    Spengler, Werner
    Eschmann, Susanne Martina
    Pfannenberg, Christina
    Al-Kamash, Fawaz
    Walles, Thorsten
    Aebert, Hermann
    Kyriss, Thomas
    Veit, Stefanie
    Kimmich, Martin
    Bamberg, Michael
    Kohlhaeufl, Martin
    Steger, Volker
    Hehr, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 942 - 948